BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
ANAHEIM, CA, March 07, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a clinical-stage developer and provider of innovative treatment programs for substance use and related disorders, has announced interim positive safety and pharmacokinetic (PK) results for the Phase I clinical trial of the Company’s BICX104 implantable naltrexone pellet. Dr. Andrew P. Mallon, PhD, the principal investigator of BioCorRx’s Phase I study, funded by the National Institute on Drug Abuse (NIDA) through the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, presented the interim findings on February 21, 2023, at the 4th Annual HEAL Investigator Meeting.
Related news for (BICX)
- BioCorRx Reports Business Update for the Second Quarter of 2024
- BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
- BioCorRx Reports Business Update for 2023
- BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
- BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors